Literature DB >> 2132503

Immunological studies in HBV-related chronic liver diseases.

N Joshi1, Q Ayesha, C M Habibullah.   

Abstract

Humoral immune response in chronic sequelae of HBV infection was assessed in the present study. Serum immunoglobulins (IgG, IgM, IgA) serum complement component C3 and C4 and circulating immune complex (CIC) were estimated in forty cases of HBsAg positive chronic active hepatitis and cirrhosis and sixty cases of age and sex matched healthy control subjects. Hypergammaglobulinemia was observed in chronic liver diseased state. All the three immunoglobulins, IgG, IgA and IgM were elevated significantly. The complement C3 and C4 were significantly decreased in patient group, while the levels of CIC were significantly increased. The increased immunoglobulin levels may be attributed to disorganised Kupffer cell system and also to B cell hyperactivity. The decreased complement levels may be attributed to decreased synthesis and/or increased consumption by increased CIC. A primary or an acquired defect in infected host to generate immune response might result in defective elimination of infected hepatocytes in chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2132503

Source DB:  PubMed          Journal:  Indian J Pathol Microbiol        ISSN: 0377-4929            Impact factor:   0.740


  2 in total

1.  Upregulation of microRNA-146a by hepatitis B virus X protein contributes to hepatitis development by downregulating complement factor H.

Authors:  Jun-Feng Li; Xiao-Peng Dai; Wei Zhang; Shi-Hui Sun; Yang Zeng; Guang-Yu Zhao; Zhi-Hua Kou; Yan Guo; Hong Yu; Lan-Ying Du; Shi-Bo Jiang; Yu-Sen Zhou
Journal:  MBio       Date:  2015-03-24       Impact factor: 7.867

2.  Screening of hepatocyte proteins binding with C‑terminally truncated surface antigen middle protein of hepatitis B virus (MHBst167) by a yeast two‑hybrid system.

Authors:  Zhi Qun Li; Enqiang Linghu; Wan Jun; Jun Cheng
Journal:  Mol Med Rep       Date:  2014-06-26       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.